Apollomics (APLMW) Stock Price, News & Analysis

Company Overview

Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and potential commercialization of novel oncology therapies. Since its founding, the company has concentrated on creating targeted and immuno-oncology candidates designed to address unmet needs in solid tumors. Apollomics maintains headquarters in the United States with key research operations in China, leveraging a dual-site strategy to accelerate global development timelines.

The company’s pipeline encompasses a range of therapeutic modalities, including monoclonal antibodies, antibody-drug conjugates and bispecific constructs. Apollomics applies proprietary target-identification and antibody-engineering platforms to advance multiple programs from preclinical stages into Phase 1 and Phase 2 clinical trials. Its lead candidates are being evaluated in various solid tumor indications, with data readouts expected to inform next-stage development and potential registration strategies.

With operations spanning both the U.S. and China, Apollomics is positioned to navigate regulatory pathways in major markets while leveraging cost-efficient R&D infrastructure. The company’s management team comprises experienced executives with backgrounds in oncology drug development, clinical operations and regulatory affairs. Apollomics continues to explore strategic collaborations to broaden its pipeline and maximize the clinical and commercial potential of its drug candidates.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.01 to $0.03
• 52-Week Range: $0.00 to $0.05
• Volume: 73,586 shs
• Average Volume: 123,607 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APLMW Stock Analysis - Frequently Asked Questions

How have APLMW shares performed this year?

Apollomics' stock was trading at $0.0092 at the start of the year. Since then, APLMW stock has increased by 160.9% and is now trading at $0.0240.

How do I buy shares of Apollomics?

Shares of APLMW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APLMW
• CIK: 1944885
• Web: www.apollomicsinc.com
• Phone: 650-209-4055
• Fax: N/A
• Employees: 59
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A